NB11 Stock Overview
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vaxart, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.81 |
| 52 Week High | US$5.98 |
| 52 Week Low | US$3.40 |
| Beta | 0.75 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -36.90% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -37.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| NB11 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | -36.9% | -17.2% | 8.2% |
Return vs Industry: NB11 underperformed the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: NB11 underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| NB11 volatility | |
|---|---|
| NB11 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NB11 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NB11's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 110 | Andy Floroiu | vaxart.com |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.
Vaxart, Inc. Fundamentals Summary
| NB11 fundamental statistics | |
|---|---|
| Market cap | €536.32m |
| Earnings (TTM) | -€78.85m |
| Revenue (TTM) | €466.76k |
1,151x
P/S Ratio-6.8x
P/E RatioIs NB11 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NB11 income statement (TTM) | |
|---|---|
| Revenue | US$471.00k |
| Cost of Revenue | US$56.88m |
| Gross Profit | -US$56.41m |
| Other Expenses | US$23.16m |
| Earnings | -US$79.56m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | -11,976.22% |
| Net Profit Margin | -16,892.57% |
| Debt/Equity Ratio | 0% |
How did NB11 perform over the long term?
See historical performance and comparison